Exome sequencing (ES) is being adopted for neurodevelopmental disorders in pediatric patients. However, little is known about current coverage policies or the evidence cited supporting these policies. Our study is the first in-depth review of private payer ES coverage policies for pediatric patients with neurodevelopmental disorders.

中文翻译：

---

儿科患者外显子组测序 (ES) 的私人付款人承保政策：随时间变化的趋势和引用的证据分析。

外显子组测序 (ES) 正被用于儿科患者的神经发育障碍。然而，人们对当前的保险政策或支持这些政策的证据知之甚少。我们的研究是第一次深入审查私人付款人 ES 覆盖政策的儿科神经发育障碍患者。